Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 12/2017

01-12-2017 | Research Article

Annual hazard rate of relapse of stage II and III colorectal cancer after primary therapy

Authors: N. Mejri, M. Dridi, S. Labidi, H. El Benna, N. Daoud, H. Boussen

Published in: Clinical and Translational Oncology | Issue 12/2017

Login to get access

Abstract

Purpose

To report the annual hazard of relapse in stages II and III colorectal cancer (CRC) Tunisian patients treated with curative intent. We also aim to evaluate impact of oxaliplatine according to anatomo-clinical features.

Methods

We collected data about clinico-pathological parameters of 331 CRCs. We analyzed annual hazard of recurrence (locoregional and/or distant) of the overall population and several subgroups: colon cancer vs rectal cancer and stage II vs stage III. We also analyzed impact of adjuvant oxaliplatine on recurrence within these subgroups.

Results

Relapse rate was 38.1%, with a mean time to relapse of 27.6 months. We noted 23.8% local recurrence, 69.8% distant recurrence, and 6.4% both. We observed higher local relapse rate in rectal cancer (26.8 vs 3.2%) vs colon cancer (p = 0.004). Stage III had a higher metastatic relapse rate vs stage II (31.6 vs 20.8%, p = 0.043). Annual hazard of recurrence for the overall population showed two peaks: [1–2] year-interval by 10.1% and [3–4] year-interval by 11.3%. Stage III showed significantly higher and earlier recurrence hazard peak compared to stage II (16.3 vs 8.1% in [1–2] year-interval). Oxaliplatine significantly improved annual hazard of recurrence in each year-interval from year 1–4, in colon cancer and in stage III but without impact in rectal cancer and stage II.

Conclusion

Extended follow-up to 4 years should be considered in Tunisian population. Impact of oxaliplatine showed same features to reported occidental series.
Literature
1.
Ben Abdallah M. Cancer registry of north of Tunisia—2004–2006. Tunis: Salah Azaiez institute; 2012.
2.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. Cancer incidence and mortality worldwide: IARC CancerBase. GLOBOCAN. 2012;1:11.
3.
André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatine, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. JCO. 2009;27:3109–16.CrossRef
4.
Schmoll H, Cartwright T, Tabernero J, Marek Nowacki, Figer Arie, Maroun Jean, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1864 patients. JCO. 2007;25(1):102–9.CrossRef
5.
Fatemi SR, Pourhoseingholi MA, Asadi F, Vahedi M, Pasha S, Alizadeh L, et al. Recurrence and five-year survival in colorectal cancer patients after surgery. IranJ Cancer Prev. 2015;8(4):e3439.
6.
Amri R, Bordeianou LG, Sylla P, Berger DL. Variations in metastasis site by primary location in colon cancer. J Gastrointestinal Surg. 2015;19(8):1522–7.CrossRef
7.
Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. JCO. 2009;27(6):872–7.CrossRef
8.
Shah MA, Renfro LA, Allegra CJ, André T, de Gramont A, Schmoll HJ, et al. Impact of patient factors on recurrence risk and time dependency of oxaliplatin benefit in patients with colon cancer: analysis from modern-era adjuvant studies in the adjuvant colon cancer end points (ACCENT) database. JCO. 2016;34(8):843–53.CrossRef
9.
André T, de Gramont A, Vernerey D, Chibaudel B, Bonnetain F, Tijeras-Raballand A, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. JCO. 2015;63:4238.
10.
Figueredo A, Rumble RB, Maroun J, Earle GC, Cummings B, McLeod R, et al. Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer. 2003;3:26.CrossRefPubMedPubMedCentral
11.
Pita-Fernandez S, Alhayek-Ai M, Gonzalez-Martin C, López-Calviño B, Seoane-Pillado T, Pértega-Díaz S. Intensive follow-up strategies improve outcomes in non-metastatic colorectal cancer patients after curative surgery. A systematic review and meta-analysis. Ann Oncol. 2014;26(4):644–56.CrossRefPubMed
12.
Halvorsen TB, Johannesen E. DNA ploidy, tumour site, and prognosis in colorectal cancer. A flow cytometric study of paraffinembedded tissue. Scand J Gastroenterol. 1990;25(2):141–8.CrossRefPubMed
13.
Li Yi, Wang Ji, Ma Xiaowei, Tan Li, Yan Yanli, Xue Chaofan. A review of neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Int J Biol Sci. 2016;12(8):1022–31.CrossRefPubMedPubMedCentral
14.
Martling AL, Holm T, Rutqvist LE, Moran BJ, Heald RJ, Cedemark B. Effect of a surgical training programme on outcome of rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke Bowel Cancer Research Project. Lancet. 2000;356(9224):93–6.CrossRefPubMed
15.
McCarthy K, Pearson K, Fulton R, Hewitt J. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev. 2012;12:CD008368.PubMed
16.
Petersen SH, Harling H, Kirkeby LT, Wille-Jorgensen P, Mocellin S. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev. 2012;3:004078.
17.
Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:200–7.CrossRefPubMed
18.
Zhao L, Liu R, Zhang Z, Li T, Li F, Liu H, et al. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials. Colorectal Dis. 2016;18(8):763–72.CrossRefPubMed
19.
Park Y, Lee KY, Kim NK, Baik SH, Sohn SK, Cho CW. Prognostic effect of perioperative change of serum carcinoembryonic antigen level: a useful tool for detection of systemic recurrence in rectal cancer. Ann Surg Oncol. 2006;13:645.CrossRefPubMed
Metadata
Title
Annual hazard rate of relapse of stage II and III colorectal cancer after primary therapy
Authors
N. Mejri
M. Dridi
S. Labidi
H. El Benna
N. Daoud
H. Boussen
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 12/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1696-0

Other articles of this Issue 12/2017

Clinical and Translational Oncology 12/2017 Go to the issue

Research Article

Tumor infiltrating lymphocytes in acral lentiginous melanoma: a study of a large cohort of cases from Latin America

Brief Research Article

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

Research Article

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

Research Article

Comparative efficacy and toxicity of induction chemotherapy with concurrent stereotactic body radiotherapy and stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma

Research Article

Haemoglobin monitoring in endometrial cancer patients undergoing radiotherapy

Research Article

Bone marrow fibrosis at diagnosis predicts survival for primary acute myeloid leukemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits